These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 17645621

  • 1. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.
    Schaefer W.
    Int J Urol; 2007 Jul; 14(7):670; author reply 670-1. PubMed ID: 17645621
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study.
    Alloussi S, Mürtz G, Braun R, Gerhardt U, Heinrich M, Hellmis E, Horn W, Marschall-Kehrel D, Niklas K, Raabe M, Rössler T, Seibt B, Siemer S, Schultz-Lampel D, Walter H, Wiedeking B, Alloussi S, Bock P, Strugala G, Madersbacher H.
    BJU Int; 2010 Aug; 106(4):550-6. PubMed ID: 20002668
    [Abstract] [Full Text] [Related]

  • 3. Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study.
    Madersbacher H, Mürtz G, Alloussi S, Domurath B, Henne T, Körner I, Niedeggen A, Nounla J, Pannek J, Schulte-Baukloh H, Schultz-Lampel D, Bock P, Strugala G.
    BJU Int; 2009 Mar; 103(6):776-81. PubMed ID: 19007380
    [Abstract] [Full Text] [Related]

  • 4. Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study.
    Stöhrer M, Mürtz G, Kramer G, Schnabel F, Arnold EP, Wyndaele JJ, Propiverine Investigator Group.
    Eur Urol; 2007 Jan; 51(1):235-42. PubMed ID: 16698176
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.
    Abrams P, Cardozo L, Chapple C, Serdarevic D, Hargreaves K, Khullar V, 1032 Study Group.
    Int J Urol; 2006 Jun; 13(6):692-8. PubMed ID: 16834644
    [Abstract] [Full Text] [Related]

  • 6. An overview on mixed action drugs for the treatment of overactive bladder and detrusor overactivity.
    Asimakopoulos AD, Cerruto MA, Del Popolo G, La Martina M, Artibani W, Carone R, Finazzi-Agrò E.
    Urol Int; 2012 Jun; 89(3):259-69. PubMed ID: 22777274
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: A randomized double-blind trial.
    Yamaguchi O, Uchida E, Higo N, Minami H, Kobayashi S, Sato H, Oxybutynin Patch Study Group.
    Int J Urol; 2014 Jun; 21(6):586-93. PubMed ID: 24350662
    [Abstract] [Full Text] [Related]

  • 8. [Efficacy and safety of propiverine on improvement of symptoms and QOL for female patients with wet overactive bladder].
    Kato M, Matsukawa Y, Kato K, Kondo A, Yamada S, Hattori R, Gotoh M.
    Hinyokika Kiyo; 2008 Mar; 54(3):165-71. PubMed ID: 18411770
    [Abstract] [Full Text] [Related]

  • 9. Oxybutynin and propiverine suppress adenosine triphosphate-induced bladder overactivity other than through antimuscarinic mechanisms.
    Moon HS, Lee JW, Park SY, Son YW, Kim YT.
    Urology; 2010 Aug; 76(2):509.e8-12. PubMed ID: 20546876
    [Abstract] [Full Text] [Related]

  • 10. Efficacy, tolerability and safety of propiverine hydrochloride in children and adolescents with congenital or traumatic neurogenic detrusor overactivity--a retrospective study.
    Grigoleit U, Mürtz G, Laschke S, Schuldt M, Goepel M, Kramer G, Stöhrer M.
    Eur Urol; 2006 Jun; 49(6):1114-20; discussion 1120-1. PubMed ID: 16542772
    [Abstract] [Full Text] [Related]

  • 11. Treatment of hyperhidrosis with oxybutynin.
    Schollhammer M, Misery L.
    Arch Dermatol; 2007 Apr; 143(4):544-5. PubMed ID: 17438194
    [No Abstract] [Full Text] [Related]

  • 12. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence.
    Madersbacher H, Halaska M, Voigt R, Alloussi S, Höfner K.
    BJU Int; 1999 Oct; 84(6):646-51. PubMed ID: 10510109
    [Abstract] [Full Text] [Related]

  • 13. [Therapy of overactive bladder with propiverine ER: results of a non-interventional study with a propiverine retard formulation and comparison to clinical studies].
    Kessler-Zumpe PL, Murgas S, Neumann G, Richter AE.
    Urologe A; 2009 Nov; 48(11):1346-51. PubMed ID: 19727644
    [Abstract] [Full Text] [Related]

  • 14. Comparison between oxybutynin, functional electrical stimulation and pelvic floor training for treatment of detrusor overactivity in women: a review.
    Arruda RM, Castro R, Sartori M, Girão MJ.
    Curr Opin Obstet Gynecol; 2009 Oct; 21(5):412-4. PubMed ID: 19593131
    [Abstract] [Full Text] [Related]

  • 15. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
    Marschall-Kehrel D, Feustel C, Persson de Geeter C, Stehr M, Radmayr C, Sillén U, Strugala G.
    Eur Urol; 2009 Mar; 55(3):729-36. PubMed ID: 18502028
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
    Staskin DR, Dmochowski RR, Sand PK, Macdiarmid SA, Caramelli KE, Thomas H, Hoel G.
    J Urol; 2009 Apr; 181(4):1764-72. PubMed ID: 19233423
    [Abstract] [Full Text] [Related]

  • 17. Gelnique (oxybutynin chloride) 10% gel for overactive bladder.
    Lajiness MJ.
    Urol Nurs; 2010 Apr; 30(4):253-4. PubMed ID: 20949812
    [Abstract] [Full Text] [Related]

  • 18. Randomized, double-blind, placebo- and propiverine-controlled trial of the once-daily antimuscarinic agent solifenacin in Japanese patients with overactive bladder.
    Yamaguchi O, Marui E, Kakizaki H, Itoh N, Yokota T, Okada H, Ishizuka O, Ozono S, Gotoh M, Sugiyama T, Seki N, Yoshida M, Japanese Solifenacin Study Group.
    BJU Int; 2007 Sep; 100(3):579-87. PubMed ID: 17669143
    [Abstract] [Full Text] [Related]

  • 19. Urodynamic effects of propiverine hydrochloride in children with neurogenic detrusor overactivity: a prospective analysis.
    Schulte-Baukloh H, Mürtz G, Henne T, Michael T, Miller K, Knispel HH.
    BJU Int; 2006 Feb; 97(2):355-8. PubMed ID: 16430646
    [Abstract] [Full Text] [Related]

  • 20. A benefit-risk assessment of extended-release oxybutynin.
    Michel MC.
    Drug Saf; 2002 Feb; 25(12):867-76. PubMed ID: 12241127
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.